Clinical Trial

Phase I Study of MT1011 Injection in Healthy Subjects

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 3, 2025 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a single-center, randomized,double-blind, placebo-controlled Phase I study to evaluate safety, PK and PD of single ascending dose (SAD) of MT1011 injection in healthy adult subjects. Includes 5 dose cohorts, with 40 subjects planned for enrollment.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-09.
Trial Details
NCT Number NCT07024160
Lead Sponsor Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Conditions Used in Patients Receiving Anticoagulant Therapy (e.g., Rivaroxaban or Apixaban, Inhibitors of Coagulation Factor Xa) Who Require Reversal of Anticoagulation
Enrollment 40 participants
Start Date 2025-06-25
Primary Completion 2026-04 (estimated)
Study Completion 2026-04 (estimated)
Updated on ClinicalTrials.gov 2025-07-03